In recent years, more and more celebrities — like Elon Musk and Whoopi Goldberg — have spoken up about using GLP-1 ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in cystic fibrosis, cancer and possibly chronic pain.

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Currax Pharmaceuticals is taking a page out of Lesley Gore’s playbook to remind patients that obesity doesn’t own them. The drugmaker launched a campaign supporting its weight loss medication ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

KEEN to lose weight in 2025? So are almost half of our readers. While weight-loss jabs, similar to Ozempic, boomed in ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.